| DIRECT COMPETITOR COMPARISON | |
| PLX | Pvt1 | GENZ | SHPGY | Industry | | Market Cap: | 761.83M | N/A | 13.45B | N/A | 104.07M | | Employees: | 138 | 1,6401 | 11,000 | N/A | 68 | | Qtrly Rev Growth (yoy): | N/A | N/A | -8.90% | N/A | 19.70% | | Revenue (ttm): | N/A | 1.32B1 | 4.61B | N/A | 14.01M | | Gross Margin (ttm): | N/A | N/A | 72.40% | N/A | 65.67% | | EBITDA (ttm): | -21.47M | N/A | 1.63B | N/A | -12.30M | | Oper Margins (ttm): | N/A | N/A | 26.10% | N/A | -149.46% | | Net Income (ttm): | -23.08M | 124.60M1 | 485.70M | N/A | N/A | | EPS (ttm): | -0.303 | N/A | 1.754 | N/A | -0.33 | | P/E (ttm): | N/A | N/A | 28.91 | N/A | 16.37 | | PEG (5 yr expected): | N/A | N/A | 1.03 | 2.2 | 1.31 | | P/S (ttm): | N/A | N/A | 2.94 | N/A | 9.43 |
|
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 56.35 | -0.27% | 57.03B | 12.29 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 46.94 | 0.04% | 13.57B | 15.71 | | Genzyme Corp. | GENZ | 50.70 | -0.72% | 13.45B | 28.91 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.11 | -0.97% | 41.50B | 17.83 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 49.78 | -0.34% | 8.88B | 1015.92 | | Teva Pharmaceutical Industries Limited | TEVA | 52.79 | -0.17% | 46.51B | 48.30 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 37.09 | 0.35% | 3.94B | 19.12 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 11.83 | -1.00% | 2.94B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 17.87 | -0.78% | 5.46B | 109.63 | | Pfizer Inc. | PFE | 18.17 | -0.44% | 146.62B | 15.09 | | Johnson & Johnson | JNJ | 62.84 | -0.08% | 173.38B | 13.72 | | GlaxoSmithKline plc | GSK | 41.47 | -1.87% | 105.13B | 13.17 | | Sanofi-Aventis | SNY | 37.96 | -1.22% | 99.12B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 55.60 | 0.40% | 126.28B | 16.65 | | RHHBY.PK | 40.92 | -1.30% | N/A | N/A | | AstraZeneca plc | AZN | 44.83 | -1.02% | 65.00B | 9.00 | | Abbott Laboratories | ABT | 54.49 | 0.76% | 84.28B | 14.76 | | Bristol-Myers Squibb Co. | BMY | 25.31 | -0.28% | 50.14B | 13.09 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | GENZ | | 'Black Friday' Data Weighs on Futures
Mon 11:29am -
at Seeking Alpha | | • | GENZ | | Baidu: Analysts' Upgrades, Dowgrades
Mon 9:30am -
at TheStreet.com | | • | GENZ | | Genzyme upgraded by Citigroup
Mon 6:29am -
Briefing.com | | • | SHPGY | | SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits
Fri, Nov 27 -
EDGAR Online | | • | GENZ | | Biotech Stock Mailbag: Targacept
Fri, Nov 27 -
at TheStreet.com | | • | GENZ | | Genzyme CEO Termeer Sells Company Shares
Wed, Nov 25 -
at Fox Business | | • | GENZ | | Dream Stocks for Biotech Investors
Wed, Nov 25 -
at Motley Fool | | • | SHPGY | | Shire's Gaucher Candidate Seeks EU Nod
Wed, Nov 25 -
Zacks.com | | • | SHPGY | | Shire moves to advance Gaucher drug
Tue, Nov 24 -
at bizjournals.com | | • | SHPGY | | Biotech Stocks: Shire climbs, Pfizer falls in early trading
Tue, Nov 24 -
at MarketWatch | | • | SHPGY | | Shire applies for Euro approval of Gaucher drug
Tue, Nov 24 -
at MarketWatch | | • | SHPGY | | Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease
Tue, Nov 24 -
PR Newswire | | | All Headlines for these symbols... |
|
|
|
0.34% Nasdaq 
0.48 (4.64%) 
Competitors
